Explore more publications!
St. Vincent & Grenadines Health Press
Got News to Share?

St. Vincent & Grenadines Health Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on St. Vincent & Grenadines Health Press.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 9, 2025

Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation
December 9, 2025

Lungpacer Achieves Commercial Milestone as Leading U.S. Hospital Performs First AeroPace® Procedures to Help Patients Liberate from Mechanical Ventilation

Indeterminate GlobeNewswire
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
December 9, 2025

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

Indeterminate GlobeNewswire
Terns Announces Proposed Public Offering
December 9, 2025

Terns Announces Proposed Public Offering

Indeterminate GlobeNewswire
Global Separation Systems Market for Commercial Biotechnology Projected to Reach $45.1 Billion by 2030
December 9, 2025

Global Separation Systems Market for Commercial Biotechnology Projected to Reach $45.1 Billion by 2030

Indeterminate GlobeNewswire
Relation announces further $26 million investment
December 9, 2025

Relation announces further $26 million investment

Indeterminate GlobeNewswire
Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders
December 9, 2025

Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders

Indeterminate GlobeNewswire
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
December 9, 2025

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases

Indeterminate GlobeNewswire
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
December 9, 2025

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

Indeterminate GlobeNewswire
2025 Assessment Finds U.S. Cities Are Taking Action to Advance Health Policy; 11 Improve Overall Medal Status
December 9, 2025

2025 Assessment Finds U.S. Cities Are Taking Action to Advance Health Policy; 11 Improve Overall Medal Status

Indeterminate GlobeNewswire
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 9, 2025

Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

Indeterminate GlobeNewswire
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
December 9, 2025

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

Indeterminate GlobeNewswire
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
December 9, 2025

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions